Molecular profiling reveals myeloid leukemia cell lines to be faithful model systems characterized by distinct genomic aberrations

To model and investigate different facets of leukemia pathogenesis, a widely accepted approach is to use immortalized leukemia cell lines. Although these provide powerful tools to our knowledge, few studies have addressed the question whether hematopoietic cell lines represent accurate and reliable model systems. To improve the molecular characterization of these model systems, we analyzed 17 myeloid leukemia cell lines using DNA microarray technology. By array-based comparative genomic hybridization, we identified recurrent genomic DNA gains and losses, as well as high-level amplifications. Parallel analysis of gene expression helped delineate potential candidate genes, and unsupervised analysis of gene expression data revealed cell lines to cluster in part based on underlying cytogenetic abnormalities. Comparison with clinical leukemia specimens showed that key signatures were retained, as myeloid cell lines with characteristic cytogenetic aberrations co-clustered with leukemia samples carrying the respective abnormality. Signatures were also quite robust, as expression data from cell lines correlated highly with published data. Thus, our analyses demonstrate myeloid cell lines to exhibit conserved and stable signatures reflecting the underlying primary cytogenetic aberrations. Our refined molecular characterization of myeloid cell lines supports the utility of cell lines as faithful and powerful model systems and provides additional insights into the molecular mechanisms of leukemogenesis.

[1]  Y. Matsuo,et al.  False leukemia–lymphoma cell lines: an update on over 500 cell lines , 2003, Leukemia.

[2]  L. Rénia,et al.  SCL/TAL1 expression level regulates human hematopoietic stem cell self-renewal and engraftment. , 2005, Blood.

[3]  J. Licht,et al.  The molecular pathology of acute myeloid leukemia. , 2005, Hematology. American Society of Hematology. Education Program.

[4]  Y. Hayashi,et al.  KIT mutations, and not FLT3 internal tandem duplication, are strongly associated with a poor prognosis in pediatric acute myeloid leukemia with t(8;21): a study of the Japanese Childhood AML Cooperative Study Group. , 2006, Blood.

[5]  D. Botstein,et al.  Cluster analysis and display of genome-wide expression patterns. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[6]  J. Harbott,et al.  Gene expression patterns associated with recurrent chromosomal translocations in acute lymphoblastic leukemia. , 2004, Blood.

[7]  B Johansson,et al.  Gene expression profiling of leukemic cell lines reveals conserved molecular signatures among subtypes with specific genetic aberrations , 2005, Leukemia.

[8]  Torsten Haferlach,et al.  AML1–ETO downregulates the granulocytic differentiation factor C/EBPα in t(8;21) myeloid leukemia , 2001, Nature Medicine.

[9]  S. Jhanwar,et al.  Frequent gain of chromosome 19 in megakaryoblastic leukemias detected by comparative genomic hybridization , 2001, Genes, chromosomes & cancer.

[10]  Jonathan R. Pollack,et al.  Characterizing the physical genome , 2002, Nature Genetics.

[11]  R. Tibshirani,et al.  Significance analysis of microarrays applied to the ionizing radiation response , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[12]  L. Feuk,et al.  Detection of large-scale variation in the human genome , 2004, Nature Genetics.

[13]  Gunnar Wrobel,et al.  Automated array-based genomic profiling in chronic lymphocytic leukemia: development of a clinical tool and discovery of recurrent genomic alterations. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[14]  G Flandrin,et al.  The World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. Report of the Clinical Advisory Committee meeting, Airlie House, Virginia, November, 1997. , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

[15]  Ash A. Alizadeh,et al.  Genome-wide analysis of DNA copy-number changes using cDNA microarrays , 1999, Nature Genetics.

[16]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[17]  L. Larizza,et al.  The Kasumi-1 cell line: a t(8;21)-kit mutant model for acute myeloid leukemia , 2005, Leukemia & lymphoma.

[18]  W. Hiddemann,et al.  1 KIT-D 816 mutations in AML 1-ETO positive AML are associated with impaired event-free and overall survival , 2005 .

[19]  J. Kang,et al.  Comprehensive genome-wide comparison of DNA and RNA level scan using microarray technology for identification of candidate cancer-related genes in the HL-60 cell line. , 2003, Cancer genetics and cytogenetics.

[20]  H. Döhner,et al.  Matrix‐based comparative genomic hybridization: Biochips to screen for genomic imbalances , 1997, Genes, chromosomes & cancer.

[21]  M. Graf,et al.  High expression of costimulatory molecules correlates with low relapse-free survival probability in acute myeloid leukemia (AML) , 2005, Annals of Hematology.

[22]  S. Fröhling,et al.  Genetics of myeloid malignancies: pathogenetic and clinical implications. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  W. Kuo,et al.  High resolution analysis of DNA copy number variation using comparative genomic hybridization to microarrays , 1998, Nature Genetics.

[24]  H. Drexler,et al.  Continuous hematopoietic cell lines as model systems for leukemia-lymphoma research. , 2000, Leukemia research.

[25]  J. Griffin,et al.  The roles of FLT3 in hematopoiesis and leukemia. , 2002, Blood.

[26]  J. Pollack,et al.  Comparative genomic hybridization on mouse cDNA microarrays and its application to a murine lymphoma model , 2005, Oncogene.

[27]  Kenny Q. Ye,et al.  Large-Scale Copy Number Polymorphism in the Human Genome , 2004, Science.

[28]  G Flandrin,et al.  World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  H. Drexler Review of alterations of the cyclin-dependent kinase inhibitor INK4 family genes p15, p16, p18 and p19 in human leukemia–lymphoma cells , 1998, Leukemia.

[30]  Gavin Sherlock,et al.  The Stanford Microarray Database accommodates additional microarray platforms and data formats , 2004, Nucleic Acids Res..

[31]  J. Shaughnessy,et al.  Retroviral integration at the Evi-2 locus in BXH-2 myeloid leukemia cell lines disrupts Nf1 expression without changes in steady-state Ras-GTP levels , 1995, Journal of virology.

[32]  N. Harris,et al.  The World Health Organization (WHO) classification of the myeloid neoplasms. , 2002, Blood.

[33]  R. Sandberg,et al.  Assessment of tumor characteristic gene expression in cell lines using a tissue similarity index (TSI). , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[34]  R. Tibshirani,et al.  Use of gene-expression profiling to identify prognostic subclasses in adult acute myeloid leukemia. , 2004, The New England journal of medicine.